ClinOne and SPRIM PRO to bring high quality solutions to clinical trials

This collaboration capitalises on ClinOne's expertise in creating seamless, site, and patient-centred clinical trial technology solutions, combined with SPRIM PRO's state-of-the-art approach to science-driven trial conduct and CRO solutions. Together, the companies aim to broaden the reach and accessibility of clinical trials, ensuring increased diversity among trial participants and caregivers, ultimately expediting the delivery of approved therapies to those in need.

The joint efforts are focused on providing an authentic Software as a Service (SaaS) model, to distinguish from competitors. This model enables user-friendly trials and comprehensive solutions for phased and post-marketing studies, ensuring both quality and scalability at a pace unmatched by others. Key features of the collaboration include innovative Consent Management, streamlined eDiary/data capture, effective rater/patient training, telehealth services, patient support programs, and medical marketing and engagement. These components play a crucial role in simplifying the trial process for participants, making it more accessible and user-friendly. Additionally, the partnership enhances patient support, access, and healthcare professional engagement post-approval through a unique combination of experience, clinical science, and innovative technology.

Andrea Valente, CEO of ClinOne, expressed excitement about the partnership, stating, "We are thrilled to partner with SPRIM PRO. This collaboration aligns perfectly with our mission to democratise the complex industry, making it more inclusive, efficient, and patient-centric."

Susan Dallabrida, CEO at SPRIM PRO, added, "Joining forces with ClinOne marks a significant step in our journey towards safely and reliably innovating healthcare solutions. Together, we are set to redefine the standards of trial design and conduct, benefiting sponsors, participants, and the broader healthcare community."

Click here to read the original news story.